副腎皮質ステロイド阻害薬市場：薬剤、治療タイプ、流通チャネル、エンドユーザー別-2024-2030年の世界予測

副腎皮質ステロイド阻害薬市場規模は2023年に24億9,000万米ドルと推計され、2024年には28億米ドルに達し、CAGR 12.75%で2030年には57億8,000万米ドルに達すると予測されています。

副腎皮質ステロイド阻害薬は、体内のコルチゾールやその他の副腎皮質ホルモンの産生や抑制作用を抑制するように設計された一群の医薬化合物です。副腎皮質ホルモンは、主に腎臓の上にある副腎で産生される一群のホルモンです。これらのホルモンは、免疫反応、炎症、ストレス、代謝、血圧など、数多くの生理的プロセスを調節しています。肥満、2型糖尿病、多嚢胞性卵巣症候群などの内分泌疾患の蔓延は、副腎皮質ホルモン阻害剤をベースとした治療に対するニーズを高める一因となっています。しかし、医薬品承認プロセスに関する規制上のハードルは、新薬の承認や適応拡大を目指す製薬企業に大幅な時間的遅れと財務的コストを課す可能性があります。さらに、有効性、特異性、副作用が改善された新薬の開発が進んでいるため、世界の最終用途部門による副腎皮質ステロイド阻害薬の使用が加速すると予想されます。

医薬品オシロドロスタット製剤の利用が急増しています。

アミノグルテチミドは旧世代の副腎ステロイド阻害剤で、副腎皮質におけるコレステロールからプレグネノロンへの変換を阻止し、コルチゾールの産生を抑制します。レボケトコナゾールは新規の治験薬で、ステロイド生成に関与する複数の酵素を阻害することによりコルチゾール合成を阻害し、内因性クッシング症候群の治療に効果を示します。メチラポンは副腎皮質ステロイド阻害薬で、コルチゾール産生の酵素である11B-水酸化酵素を阻害します。この薬剤は、クッシング症候群の急性エピソードを経験している患者に対する短期治療の選択肢として、またはコルチゾール反応性を判定するための診断ツールとして使用されます。オシロドロスタットは、11B-ヒドロキシラーゼの強力な経口阻害薬であり、クッシング病患者において、尿中遊離コルチゾールの平均値を迅速かつ持続的に低下させることが実証されています。

治療の種類クッシング症候群の治療における副腎皮質ステロイド阻害薬の使用の増加

副腎皮質ステロイド阻害薬は、ホルモン受容体陽性（HR+）転移性乳がんの治療に利用されています。HR+乳がんの第一選択薬であるアロマターゼ阻害剤に耐性となった場合に、これらの阻害剤の必要性が生じる。副腎皮質ステロイド阻害薬は、高濃度のコルチゾールに長期間さらされることによって引き起こされるホルモン障害であるクッシング症候群の管理に重要な役割を果たしています。これらの阻害薬は、コルチゾールの産生を抑制し、肥満、疲労、高血圧などのコルチゾール過剰に伴う症状を緩和することを目的としています。進行前立腺がんは、最初のホルモン療法にもかかわらず、アンドロゲンホルモンの産生が継続するために進行することが多いです。酢酸アビラテロンなどの副腎皮質ステロイド阻害薬は、アンドロゲン産生を抑制し、がんの増殖を抑えるために、コルチコステロイド薬であるプレドニゾンと併用されます。

販売チャネル：進化する副腎皮質ステロイド阻害薬のオンライン流通チャネル

副腎皮質ステロイド阻害薬の流通において、病院や診療所に入院している患者を対象とする病院薬局は重要な役割を果たしています。これらの医療施設には通常、院内に薬局があり、副腎皮質ステロイド阻害薬を含む医薬品の入手しやすさ、入手可能性を保証しています。病院の薬局は、主にメーカーやサプライヤーから直接医薬品を調達しています。宅配サービスに対する嗜好が高まる中、世界のインターネットの普及に伴い、オンライン薬局が近年急速に人気を集めています。オンライン薬局は、メーカーや正規代理店から直接調達することで品質保証を維持しつつ、ドアツードアの配送による利便性を提供しています。しかし、一部の規制のないeコマースサイトで販売されている偽造医薬品には注意が必要です。小売薬局は、世界中の住宅地に広く存在するため、依然として副腎皮質ステロイド阻害薬の流通チャネルの重要な一部です。小売薬局は、市販薬や処方箋に基づく医薬品を必要とする来店客に迅速に対応しています。

エンドユーザー：専門センターでの副腎皮質ステロイド阻害薬の大幅な採用

副腎皮質ステロイド阻害薬を使用する主な環境は病院であり、高度な診断ツールや緊急介入を必要とする総合的な治療を提供することができます。副腎がんや手術が必要な患者など、重篤な疾患や生命を脅かす疾患を持つ患者は、しばしば病院で阻害剤治療を受ける。専門センターは、特定の病状の患者に専門的な治療を提供することに重点を置いています。副腎皮質ステロイド阻害薬でいえば、これらのセンターは希少な内分泌疾患の患者に対応しており、これらの複雑な症例の管理には専門的な知識と経験が不可欠です。

地域別インサイト

南北アメリカでは、アジソン病、クッシング症候群、その他の副腎皮質疾患に対する認識が高まっていること、大手製薬企業からの研究資金が増加していること、先進的な臨床試験や新薬開発を促進する大手製薬企業との共同研究により、副腎皮質ステロイド阻害薬市場が発展しています。EU諸国では、副腎疾患の早期発見と効果的な治療法に関する意識の高まりにより、副腎皮質ステロイド阻害薬に対する需要が高まっています。EMEA地域は、各国政府がヘルスケアインフラの改善、公衆衛生意識の向上、臨床研究活動の促進に投資しているため、副腎皮質ホルモン阻害剤メーカーにとって大きなビジネスチャンスとなっています。APAC地域では、製薬会社が強固な研究開発戦略を通じて新規阻害剤を開発し、政府の政策がバイオ医薬品製造工場への投資を奨励しているため、副腎皮質ステロイド阻害薬が成長しています。さらに、オンライン薬局や流通プラットフォームの出現により、流通が拡大し、副腎皮質系疾患の治療成績が向上すると予想されます。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは副腎皮質ステロイド阻害薬市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、副腎皮質ステロイド阻害薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.副腎皮質ステロイド阻害薬市場の市場規模および予測は？

2.副腎皮質ステロイド阻害薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.副腎皮質ステロイド阻害薬市場の技術動向と規制枠組みは？

4.副腎皮質ステロイド阻害薬市場における主要ベンダーの市場シェアは？

5.副腎皮質ステロイド阻害薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 内分泌疾患の治療における副腎皮質ステロイド阻害薬の必要性の高まり
    • 副腎皮質ステロイド阻害剤ベースの薬剤に対する政府承認の増加
  • 抑制要因
    • 副腎皮質ステロイド阻害薬に関連する認知度が低く、コストが高い
  • 機会
    • 副腎皮質ステロイド阻害薬の研究開発への多額の投資
    • 洗練された医療施設の増加と医薬品分野の進歩
  • 課題
    • 副腎皮質ステロイド阻害薬をベースとした薬剤の副作用に関する懸念
• 市場セグメンテーション分析
  • 医薬品：疾患の長期治療選択肢としてオシロドロスタット薬の利用が急増
  • 治療の種類：クッシング症候群の治療における副腎皮質ステロイド阻害薬の使用増加
  • 配信チャネル：副腎皮質ステロイド阻害薬の進化するオンライン配信チャネル
  • エンドユーザー：専門センターでの副腎皮質ステロイド阻害薬の大幅な採用
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 副腎皮質ステロイド阻害薬市場薬物別

• アミノグルテチミド
• レボケトコナゾール
• メチラポン
• オシロドロスタット

第7章 副腎皮質ステロイド阻害薬市場治療の種類別

• 乳がん
• クッシング症候群
• 前立腺がん

第8章 副腎皮質ステロイド阻害薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 副腎皮質ステロイド阻害薬市場：エンドユーザー別

• 病院
• 専門センター

第10章 南北アメリカの副腎皮質ステロイド阻害薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の副腎皮質ステロイド阻害薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの副腎皮質ステロイド阻害薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • CoherusとJunshi Biosciencesが、再発性または転移性鼻咽頭がん（NPC）のすべての治療ラインでLOQTORZI（toripalimab-tpzi）のFDA承認を発表
  • 米国FDA、BRCA陽性転移性去勢抵抗性前立腺がん患者の治療薬として二重作用錠剤AKEEGA（ニラパリブとアビラテロン酢酸塩）を承認
  • モデナ社とメルク社、KEYTRUDA（R）（ペンブロリズマブ）との併用による治験中のパーソナライズmRNAがんワクチンmRNA-4157/V940が第2b相KEYNOTE-942試験で主要有効性エンドポイントを達成したことを発表
• 戦略分析と提言

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. ADRENAL CORTICOSTEROID INHIBITORS MARKET RESEARCH PROCESS
• FIGURE 2. ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. ADRENAL CORTICOSTEROID INHIBITORS MARKET DYNAMICS
• FIGURE 7. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. ADRENAL CORTICOSTEROID INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. ADRENAL CORTICOSTEROID INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ADRENAL CORTICOSTEROID INHIBITORS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY AMINOGLUTETHIMIDE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY AMINOGLUTETHIMIDE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY LEVOKETOCONAZOLE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY LEVOKETOCONAZOLE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY METYRAPONE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY METYRAPONE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY OSILODROSTAT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY OSILODROSTAT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY CUSHING'S SYNDROME, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY CUSHING'S SYNDROME, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY SPECIALITY CENTRES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY SPECIALITY CENTRES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 40. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 43. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 44. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 47. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 48. AMERICAS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 49. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 50. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 51. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 52. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 53. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 54. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 55. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 56. ARGENTINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 57. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 58. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 59. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 60. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 61. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 62. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 63. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 64. BRAZIL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 65. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 66. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 67. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 68. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 69. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 70. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 71. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 72. CANADA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 73. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 74. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 75. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 76. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 77. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 78. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 79. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 80. MEXICO ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 81. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 82. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 83. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 84. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 85. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 86. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 87. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 88. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 89. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 90. UNITED STATES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 92. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 94. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 96. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 98. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 100. ASIA-PACIFIC ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 101. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 102. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 103. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 104. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 105. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 106. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 107. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 108. AUSTRALIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 109. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 110. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 111. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 112. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 113. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 114. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 115. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 116. CHINA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 117. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 118. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 119. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 120. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 121. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 122. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 123. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 124. INDIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 125. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 126. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 127. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 128. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 129. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 130. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 131. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 132. INDONESIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 133. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 134. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 135. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 136. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 137. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 138. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 139. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 140. JAPAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 141. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 142. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 143. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 144. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 145. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 146. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 147. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 148. MALAYSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 149. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 150. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 151. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 152. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 153. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 154. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 155. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 156. PHILIPPINES ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 157. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 158. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 159. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 160. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 161. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 162. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 163. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 164. SINGAPORE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 166. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 168. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 170. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 171. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 172. SOUTH KOREA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 173. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 174. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 175. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 176. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 177. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 178. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 179. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 180. TAIWAN ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 181. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 182. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 183. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 184. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 185. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 186. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 187. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 188. THAILAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 189. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 190. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 191. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 192. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 193. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 194. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 195. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 196. VIETNAM ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 207. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 208. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 209. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 210. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 211. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 212. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 213. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 214. DENMARK ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 215. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 216. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 217. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 218. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 219. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 220. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 221. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 222. EGYPT ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 223. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 224. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 225. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 226. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 227. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 228. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 229. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 230. FINLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 231. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 232. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 233. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 234. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 235. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 236. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 237. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 238. FRANCE ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 239. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 240. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 241. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 242. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 243. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 244. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 245. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 246. GERMANY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 247. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 248. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 249. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 250. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 251. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 252. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 253. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 254. ISRAEL ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 255. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 256. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 257. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 258. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 259. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 260. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 261. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 262. ITALY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 263. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 264. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 265. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 266. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 267. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 268. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 269. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 270. NETHERLANDS ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 271. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 272. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 273. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 274. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 275. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 276. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 277. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 278. NIGERIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 279. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 280. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 281. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 282. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 283. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 284. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 285. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 286. NORWAY ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 287. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 288. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 289. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 290. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 291. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 292. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 293. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 294. POLAND ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 295. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 296. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 297. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 298. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 299. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 300. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 301. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 302. QATAR ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 303. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 304. RUSSIA ADRENAL CORTICOSTEROID INHIBITORS MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 305. RUSSIA ADRENAL CORT

[184 Pages Report] The Adrenal Corticosteroid Inhibitors Market size was estimated at USD 2.49 billion in 2023 and expected to reach USD 2.80 billion in 2024, at a CAGR 12.75% to reach USD 5.78 billion by 2030.

Adrenal corticosteroid inhibitors are a class of pharmaceutical compounds designed to suppress the production or inhibitory action of cortisol and other corticosteroids within the body. Corticosteroids are a group of hormones that are primarily produced by the adrenal glands that are located above each kidney. These hormones regulate numerous physiological processes such as immune response, inflammation, stress, metabolism, and blood pressure. Prevalence of endocrine diseases, including obesity, type 2 diabetes mellitus, and polycystic ovary syndrome, have contributed to a higher need for Adrenal corticosteroid inhibitor-based therapies. However, regulatory hurdles pertaining to drug approval processes can impose significant time delays and financial costs on pharmaceutical companies seeking approval for new drugs or expanded indications. Furthermore, the ongoing development of new drugs with improved efficacy, specificity, and reduced side effects is anticipated to accelerate the use of adrenal corticosteroid inhibitors by the end-use sectors globally.

Drug: Burgeoning utilization of osilodrostat drug owing to its long-term treatment option for diseases

Aminoglutethimide is an older-generation adrenal steroid inhibitor that stops the conversion of cholesterol to pregnenolone in the adrenal cortex, thereby reducing cortisol production. Levoketoconazole is a novel investigational drug and shows results in treating endogenous Cushing's syndrome by inhibiting cortisol synthesis by blocking multiple enzymes involved in steroidogenesis. Metyrapone is an adrenal corticosteroid inhibitor that inhibits 11B-hydroxylase, an enzyme in cortisol production. This drug is used as a short-term treatment option for patients experiencing acute episodes of Cushing's syndrome or as a diagnostic tool to determine cortisol responsiveness. Osilodrostat is a potent oral inhibitor of 11B-hydroxylase that has demonstrated rapid and sustained reductions in mean urinary-free cortisol levels in patients with Cushing's disease.

Treatment Type: Increasing use of adrenal corticosteroid inhibitors for treating cushing's syndrome

Adrenal corticosteroid inhibitors are utilized in the treatment of hormone-receptor-positive (HR+) metastatic breast cancer. The need for these inhibitors arises when patients become resistant to aromatase inhibitors, which are the first line of treatment for HR+ breast cancer. Adrenal corticosteroid inhibitors play a critical role in managing Cushing's syndrome, a hormonal disorder caused by prolonged exposure to high levels of cortisol. These inhibitors aim to reduce cortisol production and alleviate symptoms associated with cortisol excess, such as obesity, fatigue, and hypertension. Advanced prostate cancer often progresses despite initial hormone therapy due to the continued production of androgen hormones. Adrenal corticosteroid inhibitors, such as abiraterone acetate, are combined with prednisone, a corticosteroid drug, to suppress androgen production and limit cancer growth.

Distribution Channel: Evolving online distribution channel for adrenal corticosteroid inhibitors

In the distribution of adrenal corticosteroid inhibitors, hospital pharmacies play a crucial role, as they cater to patients admitted in hospitals and clinics. These medical facilities usually have an in-house pharmacy, ensuring the accessibility and availability of medications, including adrenal corticosteroid inhibitors. Hospital pharmacies mainly procure drugs directly from manufacturers or suppliers. With the growing preference for home delivery services, online pharmacies have rapidly gained popularity in recent years due to increasing internet penetration worldwide. Online pharmacies offer convenience through door-to-door deliveries while maintaining quality assurance by sourcing directly from manufacturers or authorized distributors. However, there is a need to be cautious regarding counterfeit drugs sold on some unregulated e-commerce websites. Retail pharmacies remain an integral part of the distribution channel landscape for adrenal corticosteroid inhibitors due to their widespread presence across residential areas worldwide. They serve walk-in customers who require over-the-counter or prescription-based medications promptly.

End-user: Significant adoption of adrenal corticosteroid inhibitors in specialty centers

Hospitals remain a primary setting for administering adrenal corticosteroid inhibitors owing to their ability to provide comprehensive care with access to advanced diagnostic tools and emergency intervention if required. Patients with severe or life-threatening conditions, such as adrenal carcinoma or those requiring surgery, often receive their inhibitor treatments in a hospital setting. Specialty centers focus on providing specialized care to patients with specific medical conditions. In the context of adrenal corticosteroid inhibitors, these centers cater to patients with rare endocrine disorders where expert knowledge and experience are vital in managing these complex cases.

Regional Insights

The adrenal corticosteroid inhibitors market is evolving in the Americas owing to the growing awareness of Addison's disease, Cushing's syndrome, and other adrenocortical disorders, increased research funding from the and collaboration with major pharmaceutical companies facilitating advanced clinical trials and novel drug development. In EU countries, the demand for adrenal corticosteroid inhibitors has escalated due to increased awareness about early detection and effective treatment options for adrenal diseases. The EMEA region represents a significant opportunity for adrenal corticosteroid inhibitor manufacturers as governments invest in improving healthcare infrastructure, raising public health awareness, and promoting clinical research activities. Adrenal corticosteroid inhibitors are growing in the APAC region, with pharmaceutical companies developing novel inhibitors through robust R&D strategies and government policies encouraging investment in biopharmaceutical manufacturing plants. Furthermore, the emergence of online pharmacy and distribution platforms is anticipated to expand the distribution and improve the treatment outcomes of adrenocortical medical conditions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Adrenal Corticosteroid Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Adrenal Corticosteroid Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Adrenal Corticosteroid Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adooq Bioscience LLC, Cayman Chemical Company, Crinetics Pharmaceuticals, Inc., Eli Lilly and Company, Enzo Life Sciences, Inc., Hefei Home Sunshine Pharmaceutical Technology Co., Ltd., HRA Pharma Rare Diseases SAS by Perrigo Company plc, MedChemExpress, Merck KGaA, Novartis AG, Orphagen Pharmaceuticals, Pfizer Inc., Sparrow Pharmaceuticals Inc., Steris Healthcare PVT Ltd, Tocris Bioscience by Bio-Techne Corporation, and Xeris Biopharma Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Adrenal Corticosteroid Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug
  • Aminoglutethimide
  • Levoketoconazole
  • Metyrapone
  • Osilodrostat

• Treatment Type
  • Breast Cancer
  • Cushing's Syndrome
  • Prostate Cancer

• Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

• End-user
  • Hospitals
  • Speciality Centres

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Adrenal Corticosteroid Inhibitors Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Adrenal Corticosteroid Inhibitors Market?

3. What are the technology trends and regulatory frameworks in the Adrenal Corticosteroid Inhibitors Market?

4. What is the market share of the leading vendors in the Adrenal Corticosteroid Inhibitors Market?

5. Which modes and strategic moves are suitable for entering the Adrenal Corticosteroid Inhibitors Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing need for adrenal corticosteroid inhibitors to treat endocrine diseases
    • 5.1.1.2. Rising government approvals for adrenal corticosteroid inhibitors-based drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Limited awareness and high cost associated with adrenal corticosteroid inhibitors
  • 5.1.3. Opportunities
    • 5.1.3.1. Significant investments in research and development of adrenal corticosteroid inhibitors
    • 5.1.3.2. Growing presence of refined medical facilities and advances in pharmaceutical sector
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns regarding side impacts of adrenal corticosteroid inhibitors-based drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug: Burgeoning utilization of osilodrostat drug owing to its long-term treatment option for diseases
  • 5.2.2. Treatment Type: Increasing use of adrenal corticosteroid inhibitors for treating cushing's syndrome
  • 5.2.3. Distribution Channel: Evolving online distribution channel for adrenal corticosteroid inhibitors
  • 5.2.4. End-user: Significant adoption of adrenal corticosteroid inhibitors in specialty centers
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Adrenal Corticosteroid Inhibitors Market, by Drug

• 6.1. Introduction
• 6.2. Aminoglutethimide
• 6.3. Levoketoconazole
• 6.4. Metyrapone
• 6.5. Osilodrostat

7. Adrenal Corticosteroid Inhibitors Market, by Treatment Type

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Cushing's Syndrome
• 7.4. Prostate Cancer

8. Adrenal Corticosteroid Inhibitors Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Online Pharmacy
• 8.4. Retail Pharmacy

9. Adrenal Corticosteroid Inhibitors Market, by End-user

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Speciality Centres

10. Americas Adrenal Corticosteroid Inhibitors Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Adrenal Corticosteroid Inhibitors Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Adrenal Corticosteroid Inhibitors Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
  • 13.3.2. U.S. FDA Approves AKEEGA (Niraparib and Abiraterone Acetate), the Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
  • 13.3.3. Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
• 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio